GOT1 and pancreatic adenocarcinoma: The GOT1 expression levels were significantly increased in lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), pancreatic adenocarcinoma (PAAD) and thymoma (THYM), while the levels were significantly decreased in glioblastoma multiforme (GBM), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), brain lower grade glioma (LGG) and testicular germ cell tumors (TGCT).